Cited by 174Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase SignalingCancer Genomics and Diagnostics

The DOI matches its Crossref record.

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Fakih, Marwan, O'Neil, Bert, Price, Timothy Jay, Falchook, Gerald Steven, Desai, Jayesh, Kuo, James, Govindan, Ramaswamy, Rasmussen, Erik, Morrow, Phuong Khanh H., Ngang, Jude, Henary, Haby A., Hong, David S.·2019·Journal of Clinical Oncology

DOI 10.1200/jco.2019.37.15_suppl.3003

Open this paper in CoChat — free account

Abstract

3003 Background: The KRAS G12C mutation is found in approximately 13% of lung adenocarcinomas and 1–3% of other solid tumors, but there is no approved therapy that targets this mutation. AMG 510 is a novel small molecule that specifically and irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Methods: This phase 1, first-in-human, open-label, multicenter study (NCT03600883) is evaluating the safety, tolerability, PK, and efficacy of AMG 510 in adult patients (pts) with locally-advanced or metastatic KRAS G12C mutant solid tumors. The primary endpoint is safety; key secondary endpoints include PK, ORR (assessed every 6 weeks [wks]), DOR, and PFS. Key inclusion criteria: KRAS G12C mutation identified through DNA sequencing, measurable or evaluable disease, ECOG PS ≤2, life expectancy >3 months (mo). Key exclusion criteria: active brain metastases, myocardial infarction within 6 mo. A dose exploration will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). A dose expansion will enroll pts with NSCLC, CRC, and other advanced solid tumors carrying the KRAS G12C mutation. AMG 510 will be given PO until disease progression, intolerance, or withdrawal of consent. Results: 22 pts (8 men, 14 women; median age 55.5 y) were enrolled in the first 3 dose cohorts. Tumor types: 6 NSCLC, 15 CRC, 1 other. Most pts (n=17) had ≥3 prior lines of treatment (tx). Median tx duration was 28 d (range: 8–134). 5 pts reported 10 treatment-related AEs (grade 1, n=9; grade 2, n=1); there were no DLTs. Tumor response was evaluated in 9 pts (4 with ≥2 assessments); 13 pts have not reached their first assessment.1 pt had a PR (NSCLC at wks 6 and 12, tx ongoing), 6 pts had SD (4 CRC and 2 NSCLC; median tx duration 9.7 wks [range: 6.3–19.1], tx ongoing), 2 pts had PD. 20 pts are continuing to receive AMG 510. A second PR (NSCLC at wk 6, tx ongoing) was reported after data cutoff. Conclusions: AMG 510 has been well tolerated at the dose levels tested and has shown antitumor activity when administered as monotherapy to patients with advanced KRAS G12C mutant solid tumors. MTD has not been determined, and enrollment into the dose exploration is ongoing. Clinical trial information: NCT03600883.

Integrity signals

Registry

Crossref · 10.1200/jco.2019.37.15_suppl.3003

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Still being checked.

Sorted by citations

Targeting apoptosis in cancer therapy
Carneiro, B. A., & El‐Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,676
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Mosele, F., Remón, J., Mateo, J., Westphalen, C. B., Barlési, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M. E., Meric‐Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,235
Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01180 · Cited by 765
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Degirmenci, U., Wang, M., & Hu, J. (2020) · Cells · doi:10.3390/cells9010198 · Cited by 562
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0142 · Cited by 444
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M. M., & Garrido‐Laguna, I. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 403
Emerging therapeutic agents for advanced non-small cell lung cancer
Chen, R., Manochakian, R., James, L. E., Azzouqa, A., Shi, H., Zhang, Y., Zhao, Y., Zhou, K., & Lou, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00881-7 · Cited by 347
Crystal structure of human KRAS G12C covalently bound to a phthalazine inhibitor
Mohr, C. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6pgo/pdb · Cited by 313
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer
Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250
Emerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 247
Treatment landscape of metastatic pancreatic cancer
Dosso, S. D., Siebenhüner, A. R., Winder, T., Meisel, A., Fritsch, R., Astaras, C., Szturz, P., & Borner, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102180 · Cited by 212
Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
Judd, J., Karim, N. A., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., VanderWalde, A. M., Mamdani, H. M., Raez, L. E., Nagasaka, M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0201 · Cited by 209
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101974 · Cited by 185
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
Salgia, R., Pharaon, R. R., Mambetsariev, I., Nam, A., & Sattler, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100186 · Cited by 173
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Singh, R., & O'Reilly, E. M. (2020) · Drugs · doi:10.1007/s40265-020-01304-0 · Cited by 158
A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy
Zhang, Z., Rohweder, P. J., Ongpipattanakul, C., Basu, K., Bohn, M.-F., Dugan, E. J., Steri, V., Hann, B., Shokat, K. M., & Craik, C. S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.005 · Cited by 136
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Zhang, Z., Gao, R., Hu, Q., Peacock, H., Peacock, D. M., Dai, S., Shokat, K. M., & Suga, H. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00514 · Cited by 124
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
Tan, A. C., Lai, G. G. Y., Tan, G. S., Poon, S. Y., Doble, B., Lim, T. H., Aung, Z. W., Takano, A. M., Tan, W. L., Ang, M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.022 · Cited by 121
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Friedlaender, A., Drilon, A., Weiss, G. J., Banna, G. L., & Addeo, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101978 · Cited by 118
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 133
Current therapy of KRAS-mutant lung cancer
Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
Chen, H., Smaill, J. B., Liu, T., Ding, K., & Lu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01312 · Cited by 104
The Crossroads between RAS and RHO Signaling Pathways in Cellular Transformation, Motility and Contraction
Soriano, O., Pérez, M. A., Vicente‐Manzanares, M., & Castellano, E. (2021) · Genes · doi:10.3390/genes12060819 · Cited by 107
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Stalnecker, C. A., & Der, C. J. (2020) · Science Signaling · doi:10.1126/scisignal.aay6013 · Cited by 90
Strategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
Okusaka, T., & Furuse, J. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01666-y · Cited by 88
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C
Kettle, J. G., Bagal, S. K., Bickerton, S., Bodnarchuk, M. S., Breed, J., Carbajo, R. J., Cassar, D. J., Chakraborty, A., Cosulich, S. C., Cumming, I. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01720 · Cited by 84
Histology-agnostic drug development — considering issues beyond the tissue
Pestana, R. C., Sen, S., Hobbs, B. P., & Hong, D. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0384-0 · Cited by 82
Self-citation
Cancer of Unknown Primary in the Molecular Era
Kato, S., Alsafar, A., Walavalkar, V., Hainsworth, J. D., & Kurzrock, R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.11.002 · Cited by 77
Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics
Santana-Codina, N., Chandhoke, A. S., Yu, Q., Małachowska, B., Kuljanin, M., Gikandi, A., Stańczak, M., Gableske, S., Jedrychowski, M. P., Scott, D. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.021 · Cited by 77
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma
McIntyre, C. A., Lawrence, S., Richards, A. L., Chou, J. F., Wong, W., Capanu, M., Berger, M. F., Donoghue, M. T. A., Yu, K. H., Varghese, A. M., et al. (2020) · Cancer · doi:10.1002/cncr.33038 · Cited by 75
Therapeutics Targeting Mutant KRAS
Thein, K. Z., Biter, A. B., & Hong, D. S. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-033145 · Cited by 76
Self-citation
A bright future for KRAS inhibitors
Bar-Sagi, D., Knelson, E. H., & Sequist, L. V. (2020) · Nature Cancer · doi:10.1038/s43018-019-0016-8 · Cited by 74
Current Approaches in NSCLC Targeting K-RAS and EGFR
Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Molina‐Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 76
Molecular Pathology of Lung CancerPreprint
Saller, J. J., & Boyle, T. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037812 · Cited by 83
The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience
Torralvo, J., Friedlaender, A., Achard, V., & Addeo, A. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20160 · Cited by 71
Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts
Dunnett-Kane, V., Burkitt-Wright, E., Blackhall, F. H., Malliri, A., Evans, D. G., & Lindsay, C. R. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.291 · Cited by 66
Bifunctional Small‐Molecule Ligands of K‐Ras Induce Its Association with Immunophilin Proteins
Zhang, Z., & Shokat, K. M. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201910124 · Cited by 66
Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS
Pinheiro, G., Pereira, T., Dias, C., Freitas, C., Hespanhol, V. P., Costa, J. L., Cunha, A. M. T. D. S., & Oliveira, H. P. (2020) · Scientific Reports · doi:10.1038/s41598-020-60202-3 · Cited by 70
Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
Boonstra, P. A., Wind, T. T., van Kruchten, M., Schuuring, E. M. D., Hospers, G. A. P., van der Wekken, A. J., de Groot, D. J. A., Schröder, C. P., Fehrmann, R. S. N., & Reyners, A. K. L. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09876-9 · Cited by 60
Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties
Song, H., Wu, J., Tang, Y., Dai, Y., Xiang, X., Li, Y., Wu, L., Wu, J., Liang, Y., Xing, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9155 · Cited by 56
Harnessing the potential of CD40 agonism in cancer therapy
Zhou, Y., Richmond, A. J., & Yan, C. W. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.002 · Cited by 55
Post-translational modification of KRAS: potential targets for cancer therapy
Wang, W., Yuan, T., Qian, M., Yan, F., Yang, L., He, Q., Yang, B., Lu, J., & Zhu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00542-y · Cited by 54
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
Goldman, J. W., Mazieres, J., Barlesi, F., Dragnev, K. H., Koczywas, M., Göskel, T., Cortot, A. B., Girard, N., Wesseler, C., Bischoff, H., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.578756 · Cited by 52
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Martini, G., Dienstmann, R., Ros, J., Baraibar, I., Cuadra‐Urteaga, J. L., Salvà, F., Ciardiello, D., Mulet-Margalef, N., Argilés, G., Tabernero, J. M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936089 · Cited by 57
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 48
Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway
Jain, A. S., Prasad, A., Pradeep, S., Dharmashekar, C., Achar, R. R., Silina, E. V., Stupin, V. A., Amachawadi, R. G. G., Prasad, S. K., Pruthvish, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741326 · Cited by 51
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines
Passiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 48
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
Nokin, M., Darbo, É., Travert, C., Drogat, B., Lacouture, A., José, S. S., Cabrera-Benítez, N. E., Turcq, B., Prouzet‐Mauleon, V., Falcone, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137869 · Cited by 47
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges
Passiglia, F., Malapelle, U., Re, M. D., Righi, L., Pagni, F., Furlan, D., Danesi, R., Troncone, G., & Novello, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.023 · Cited by 43
Comprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancer
Kondo, T., Matsubara, J., Quy, P. N., Fukuyama, K., Nomura, M., Funakoshi, T., Doi, K., Sakamori, Y., Yoshioka, M., Yokoyama, A., et al. (2020) · Cancer Science · doi:10.1111/cas.14674 · Cited by 41
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy
Noordhof, A. L., Damhuis, R. A. M., Hendriks, L. E. L., Langen, A. J. D., Timens, W., Venmans, B. J. W., & van Geffen, W. H. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.001 · Cited by 42
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
Chen, Y., Liu, Q.-P., Xie, H., & Ding, J. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01194-4 · Cited by 45
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
Singh, A. P., Shum, E., Rajdev, L. N., Cheng, H., Goel, S., Perez-Soler, R., & Halmos, B. (2020) · Cancers · doi:10.3390/cancers12051156 · Cited by 40
Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
Ji, J., Wang, C., & Fakih, M. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s340392 · Cited by 39
Self-citation
Differential Outcomes in Codon 12/13 and Codon 61 NRAS -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS -Mutated Tumors
Cleary, J. M., Wang, V., Heist, R. S., Kopetz, S., Mitchell, E. P., Zwiebel, J. A., Kapner, K. S., Chen, H. X., Li, S., Gray, R. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0066 · Cited by 38
Direct Ras G12C inhibitors: crossing the rubicon
Lindsay, C. R., & Blackhall, F. H. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0499-1 · Cited by 40
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Batrash, F., Kutmah, M., & Zhang, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00453-8 · Cited by 42
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
Lai, E., Liscia, N., Donisi, C., Mariani, S., Tolu, S., Pretta, A., Persano, M., Pinna, G., Balconi, F., Pireddu, A., et al. (2020) · Cancers · doi:10.3390/cancers12051214 · Cited by 37
The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
Elsayed, M., & Abdelrahim, M. (2021) · Biomedicines · doi:10.3390/biomedicines9040389 · Cited by 37
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 33
Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer
Yagisawa, M., Sawada, K., Nakamura, Y., Fujii, S., Yuki, S., Komatsu, Y., Yoshino, T., Sakamoto, N., & Taniguchi, H. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.11.002 · Cited by 36
Targeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 39
Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis
Bian, Y., Shan, G., Bi, G., Liang, J., Hu, Z., Sui, Q., Shi, H., Zheng, Z., Yao, G., Wang, Q., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103361 · Cited by 34
A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
Lei, L., Wang, W., Yu, Z., Liang, X., Pan, W., Chen, H., Wang, L., Fang, Y., Wang, M., Xu, C., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.12.004 · Cited by 35
Targeting KRAS in Colorectal Cancer
Wang, C., & Fakih, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01022-0 · Cited by 35
Self-citation
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 34
KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
Ceddia, S., Landi, L. M., & Cappuzzo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169391 · Cited by 35
The Emerging Role of Ras Pathway Signaling in Pediatric Cancer
Ney, G. M., McKay, L. M., Koschmann, C. J., Mody, R. J., & Li, Q. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0916 · Cited by 32
Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods
Kulkarni, A. M., Kumar, V., Parate, S., Lee, G., Yoon, S., & Lee, K. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031309 · Cited by 32
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives
Genova, C., Rossi, G., Tagliamento, M., Rijavec, E., Biello, F., Cerbone, L., Zullo, L., & Grossi, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1714441 · Cited by 27
Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
Nyíri, K., Koppány, G., & Vértessy, B. G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09914-6 · Cited by 27
Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy
Olaoba, O. T., Adelusi, T. I., Yang, M. J., Maidens, T., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Cancers · doi:10.3390/cancers16101808 · Cited by 28
Targeted Therapy for Non-Small Cell Lung Cancer
Noor, Z. S., Cummings, A. L., Johnson, M. M., Spiegel, M. L., & Goldman, J. W. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1700994 · Cited by 27
Small molecule inhibitors of RAS proteins with oncogenic mutations
Orgován, Z., & Keserű, G. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09911-9 · Cited by 25
Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma
Kneuertz, P. J., Carbone, D. P., D’Souza, D. M., Shilo, K., Abdel‐Rasoul, M., Zhao, W., Williams, T. M., Jones, D. R., & Merritt, R. E. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.012 · Cited by 23
Small molecule combats cancer-causing KRAS protein at last
Herbst, R. S., & Schlessinger, J. (2019) · Nature · doi:10.1038/d41586-019-03242-8 · Cited by 23
Prediction of Target-Drug Therapy by Identifying Gene Mutations in Lung Cancer With Histopathological Stained Image and Deep Learning Techniques
Huang, K., Mo, Z., Zhu, W. Q., Liao, B., Yang, Y., & Wu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642945 · Cited by 22
Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C
Zhuang, H., Fan, J., Li, M., Zhang, H., Yang, X., Lin, L., Lu, S., Wang, Q., & Liu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.915512 · Cited by 23
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
Gianoncelli, L., Spitaleri, G., Passaro, A., Radice, D., Fumagalli, C., Signore, E. D., Stati, V., Catania, C., Guerini‐Rocco, E., Barberis, M. C. P., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13970 · Cited by 22
Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome
Shoucair, S., Habib, J. R., Pu, N., Kinny‐Köster, B., van Oosten, A. F., Javed, A. A., Lafaro, K. J., He, J. P., Wolfgang, C. L., & Yu, J. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11081-z · Cited by 20
An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances
Tateo, V., Manuzzi, L., Parisi, C., Giglio, A. D., Campana, D., Pantaleo, M. A., & Lamberti, G. (2021) · Pharmaceuticals · doi:10.3390/ph14040316 · Cited by 20
KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
García-Robledo, J. E., Rosell, R., Ruíz-Patiño, A., Sotelo, C., Arrieta, O. G., Zatarain-Barrón, L., Ordóñez‐Reyes, C., Jaller, E., Rojas, L., Russo, A., et al. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211066064 · Cited by 22
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma
Daemen, A., Cooper, J. E., Myrta, S., Wongchenko, M. J., Lin, E., Long, J. E., Foreman, O., Modrusan, Z. D., Tremayne, J. R., de la Cruz, C. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1835 · Cited by 20
Validated HPLC‐MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice
Madhyastha, N., Samantha, S. K., Dittakavi, S., Markose, M., Mallurwar, S. R., Zainuddin, M., & Mullangi, R. (2020) · Biomedical Chromatography · doi:10.1002/bmc.5043 · Cited by 20
Loss of wild type KRAS in KRAS lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors
Liu, Y., Gao, G. F., Minna, J. D., Williams, N. S., & Westover, K. D. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2020.12.032 · Cited by 20
Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors
Li, B., Rong, D., & Wang, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191011163410 · Cited by 20
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
Vaclová, T., Chakraborty, A., Sherwood, J. L., Ross, S. J., Carroll, D. K., Barrett, J. C., Downward, J., & de Bruin, E. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-06369-3 · Cited by 20
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
Ruppert, A.-M., Beau‐Faller, M., Debieuvre, D., Ouafik, L., Westeel, V., Rouquette, I., Mazières, J., Bringuier, P., Monnet, I., Escande, F., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100052 · Cited by 19
Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma
Kim, J. H., Yoon, S., Lee, K. H., Jang, S. J., Chun, S., & Kim, S. (2021) · Cancer Medicine · doi:10.1002/cam4.3874 · Cited by 19
The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification
Yang, Y., Ding, Y., Gong, Y., Zhao, S., Li, M., Li, X., Song, G., Zhai, B., Liu, J., Shao, Y. W., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09279-9 · Cited by 19
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
Toomey, S., Carr, A., Mezynski, J., Elamin, Y. Y., Rafee, S., Cremona, M., Morgan, C., Madden, S. F., Jalil, K. I. A., Gately, K. A., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02273-4 · Cited by 17
Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review
Mansinho, A., Fernandes, R. M., & Carneiro, A. V. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02362-4 · Cited by 18

Authors: Fakih, M., O'Neil, B., Price, T. J., Falchook, G. S., Desai, J., Kuo, J., Govindan, R., Rasmussen, E., Morrow, P. K. H., Ngang, J., Henary, H. A., & Hong, D. S.
Affiliations: City Of Hope National Medical Center (US)
Indiana University School of Medicine, Indianapolis, IN;
Queen Elizabeth Hospital (AU)
HealthONE (US)
Peter MacCallum Cancer Centre (AU)
Scientia Clinical Research, Randwick, Australia;
Washington University in St. Louis (US)
Amgen (United States) (US)
The University of Texas MD Anderson Cancer Center (US)
ORCID: Fakih, Marwan
Price, Timothy Jay
Falchook, Gerald Steven
Desai, Jayesh
Kuo, James
Govindan, Ramaswamy
Morrow, Phuong Khanh H.
Hong, David S.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2019-05-20
Volume: 37
Issue: 15_suppl
Pages: 3003-3003
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2019.37.15_suppl.3003
OpenAlex: W2947477797
Cited by: 172
References: 0
Citations by year: 2025: 3 · 2024: 6 · 2023: 12 · 2022: 21 · 2021: 34 · 2020: 75 · 2019: 20
Type: conference abstract
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: sotorasib, KRAS G12C inhibitors, KRAS G12C mutation, advanced solid tumors, non-small cell lung cancer, colorectal cancer, pharmacokinetics, safety and tolerability, maximum tolerated dose, objective response rate, progression-free survival, dose escalation, dose expansion, treatment-related adverse events

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks